Jump to: 5-Amino-1MQ · Adipotide · AHK-Cu · AZD6234 · Biotinoyl Tripeptide-1 · BPC-157 · BRN2 (POU3F2) Research Peptide · Bronchogen · Cagrilintide · CagriSema · Cecropin · Cerluten · Chonluten · CJC-1295 · CNP · Cortagen · Danuglipron · Dihexa · DSIP · ECC5004 · Eftansomatropin alfa · Endoluten · Enlicitide · Epithalon · Exenatide · FGL Peptide · FOXO4-DRI · GHK-Cu · GLP-1 · Glucagon · Gonadorelin · HRS-9531 · Icotrokinra · Insulin efsitora alfa · Insulin icodec · Ipamorelin · KN056 · KPV · KR-12 · Liraglutide · LL-37 · Mazdutide · Melanotan II · Mod GRF 1-29 · MOTS-c · NA-Selank Amidate · Navepegritide · NPAS3 Research Peptide · Orforglipron · Palmitoyl Tetrapeptide-7 · Palmitoyl Tripeptide-38 · Palopegteriparatide · Parathyroid hormone (1-84) · PB-718 · PEG-MGF · Petrelintide · Prostamax · PT-141 · Retatrutide · Rusfertide · Semaglutide · Semax · Sermorelin · Somatropin (HGH) · Survodutide · Syn-Ake · TB-500 · Teriparatide · Tesamorelin · Testagen · Thymosin β4 · Tirzepatide · Trevogrumab · Ventfort · Vesugen · Visoluten · VK2735 · Vosoritide
Want everything? The site feed carries every Wire post, and the regulatory alerts feed every rule change. Corrections are dated by the day the fix went live; the full log is on corrections.
Tirzepatide
RSS feed for Tirzepatide · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · News · How Many Americans Take a GLP-1? What Gallup's Surveys Actually Say
- · News · Berobenatide: Pfizer's Monthly GLP-1 Peptide Is Now in Eleven Phase 3 Trials
- · News · VK2735: Viking Starts Its Oral Phase 3 Trials and Reports Less-Frequent Maintenance Dosing
- · News · CagriSema Against Tirzepatide in Type 2 Diabetes: What REIMAGINE 5 Shows
- · News · EloraTZP Phase 2b: 23.3% Weight Loss in Type 2 Diabetes, and Up to 27% Stopped for Side Effects
- · Regulatory alert · US FDA: FDA warned a Houston compounding pharmacy that its tirzepatide with niacinamide and semaglutide with vitamin B12 appear to be essentially copies of approved GLP-1 drugs, made in volumes suggesting the added vitamin is pretextual. Posted September 22.
Adding a vitamin does not by itself make a compounded GLP-1 lawful. The statute's condition is a prescriber's documented, patient-specific significant difference; pre-written prescriber determinations were part of FDA's case. - · Regulatory alert · Netherlands (IGJ): The Dutch health inspectorate imposed a penalty order on the online seller it had ordered on August 24 to stop selling retatrutide, tirzepatide and semaglutide, after the seller kept selling.
Dutch enforcement moved from an order to escalating penalties within a week. Retatrutide is approved nowhere, and the two approved GLP-1s are prescription medicines that a webshop may not supply. - · Regulatory alert · Netherlands (IGJ): The Dutch health inspectorate ordered an online webshop trading under several names to end the supply, delivery and trade of medicines containing retatrutide, tirzepatide and semaglutide.
In the EU, selling these as 'peptides' online does not take them outside medicines law; the inspectorate treats them as medicines supplied without the required licences. - · Regulatory alert · US FDA: FDA sent warning letters to five online peptide sellers in North Carolina, Florida, Texas and Arizona, calling retatrutide, semaglutide, tirzepatide and other peptides unapproved new drugs. Posted September 1.
A 'research use only' label did not decide the case: FDA read intended use from the whole website. Selling bacteriostatic water and offering a peptide calculator counted as evidence of human use. - · Regulatory alert · US FDA: FDA extended the comment period on its proposal not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list by 30 days, to July 30, 2026 (91 FR 38719).
Comments are closed. As of November 2, 2026 the Federal Register held no final determination: the June 26 extension is the newest document in docket FDA-2018-N-3240. - · News · A Single Peptide That Hits Five Receptors: The Quintuple Agonist
- · Regulatory alert · US FDA: FDA warned a Chinese maker of peptide ingredients, including semaglutide and tirzepatide, over manufacturing-quality failures and relabelling semaglutide bought from other suppliers as its own. It had been put on Import Alert 66-40 and removed from the Import Alert 66-80 Green List on February 27. Posted May 19.
The quality problem FDA describes sits upstream of any vial: the ingredient, and who really made it. Compounders depend on that ingredient, and 503A pharmacies are exempt from the manufacturing rules that would catch it. - · Regulatory alert · US FDA: FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431, docket FDA-2018-N-3240).
A proposal, not a rule. It concerns outsourcing facilities compounding from bulk when there is no shortage; the three were never on the list, so nothing was removed. - · Regulatory alert · US FDA: FDA warned an outsourcing facility making tirzepatide and semaglutide after inspectors recovered mould during a tirzepatide run and found products released despite microbial recoveries.
Even regulated compounders fail sterility; the firm had recalled multidose vials. A grey-market vial has no inspection at all before it ships. - · Regulatory alert · US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.
The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence. - · Regulatory alert · US FDA: FDA warned a state-licensed compounding pharmacy that released products, including a compounded tirzepatide injection, among nine lots that failed sterility testing.
A compounded GLP-1 is only as safe as the pharmacy's sterile practice; checking that a pharmacy is licensed and has no recent FDA letter is part of choosing one. - · Regulatory alert · US FDA: FDA launched a 'Green List' import alert (66-80): GLP-1 ingredients such as semaglutide and tirzepatide from foreign sites it has not found compliant can be detained without physical examination.
It is aimed at ingredients for compounding, not at personal parcels: ingredients from sites on the Green List can still be imported. - · Regulatory alert · US FDA: FDA's enforcement discretion for outsourcing facilities compounding tirzepatide ended.
Outsourcing facilities lost the shortage-era route to compounding tirzepatide. - · Regulatory alert · US FDA: FDA's enforcement discretion for 503A pharmacies compounding tirzepatide copies ended when a court denied a preliminary injunction.
State-licensed pharmacies lost the routine route to compounding tirzepatide first.
Thymosin β4
RSS feed for Thymosin β4 · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.
Tesamorelin
RSS feed for Tesamorelin · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.
TB-500
RSS feed for TB-500 · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · New guide · TB-500: the legal prescription route
Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found. - · News · Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30
- · Regulatory alert · US HHS (Office of the Secretary): HHS published a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon under set forms, routes and conditions, while FDA writes the 503A bulks list by rulemaking (91 FR 68526).
Enforcement discretion, not a rule or an approval: the policy is non-binding, HHS may revisit it, and the conditions cover sourcing, a certificate of analysis, one peptide per product, labelling, an FDA-cleared syringe and adverse-event reporting. None of the six is on the 503A list or in Category 1; emideltide is not covered, and products sold outside a pharmacy are not covered. - · Regulatory alert · US FDA advisory committee: The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for FDA's 503A bulks list and voted against emideltide, as reported (BPC-157 8–6, 1 abstention; KPV 8–6, 1 abstention; TB-500 8–6, 1 abstention; MOTS-c 7–5, 2 abstentions; emideltide 6–7, 1 abstention; semax 8–5, 1 abstention; epitalon 7–4 or 7–5, 1 abstention).
A committee recommendation is not a rule. As of November 4, 2026, FDA had posted no minutes or tallies, its 503A category list was still dated May 14, 2026, and none of the six was on the list or in Category 1. HHS's October 30 enforcement-discretion policy, logged separately, covers compounding of the six under its conditions; it does not add them to the list. - · Regulatory alert · Brazil (ANVISA): Brazil's health regulator said GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category and are illegal for any health or aesthetic use.
In Brazil an injectable peptide cannot be sold as a supplement or a cosmetic: supplements cannot be injectable and injectable cosmetics do not exist in its rules. - · Regulatory alert · France (ANSM): France's medicines agency told the public not to buy or inject peptides sold online, on social media or through informal contacts, naming retatrutide, BPC-157, TB-500 and GHK-Cu among others. Updated August 31.
In France these products are neither evaluated nor authorised, and their contents are uncertain. Anyone who has used them and has side effects should see a health professional. - · Regulatory alert · US FDA: FDA's list of substances that may present significant safety risks now shows twelve peptides, including BPC-157, TB-500, KPV and MOTS-c, among nominations withdrawn, so they are no longer in Category 2.
Off Category 2 is not cleared: none moved to Category 1 or onto the 503A list, so 503A pharmacies still cannot compound them. Seven went to the July committee; five wait for a meeting before the end of February 2027. - · Regulatory alert · US FDA: FDA gave notice in the Federal Register (91 FR 20465) of a July 23-24, 2026 committee meeting on seven peptides nominated for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.
The first public review of these peptides for compounding, with a public docket (FDA-2025-N-6895) that took comments until July 22.
Survodutide
RSS feed for Survodutide · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · News · SYNCHRONIZE-2: Survodutide Reaches 13.1% Weight Loss in Type 2 Diabetes, and 18% Stopped for Side Effects
- · News · SYNCHRONIZE-1: Survodutide Hits 16.6% Weight Loss in Phase 3
Sermorelin
RSS feed for Sermorelin · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.
Semax
RSS feed for Semax · Encyclopedia entry
- · New guide · Semax: the legal prescription route
Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found. - · News · Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30
- · Regulatory alert · US HHS (Office of the Secretary): HHS published a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon under set forms, routes and conditions, while FDA writes the 503A bulks list by rulemaking (91 FR 68526).
Enforcement discretion, not a rule or an approval: the policy is non-binding, HHS may revisit it, and the conditions cover sourcing, a certificate of analysis, one peptide per product, labelling, an FDA-cleared syringe and adverse-event reporting. None of the six is on the 503A list or in Category 1; emideltide is not covered, and products sold outside a pharmacy are not covered. - · Regulatory alert · US FDA advisory committee: The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for FDA's 503A bulks list and voted against emideltide, as reported (BPC-157 8–6, 1 abstention; KPV 8–6, 1 abstention; TB-500 8–6, 1 abstention; MOTS-c 7–5, 2 abstentions; emideltide 6–7, 1 abstention; semax 8–5, 1 abstention; epitalon 7–4 or 7–5, 1 abstention).
A committee recommendation is not a rule. As of November 4, 2026, FDA had posted no minutes or tallies, its 503A category list was still dated May 14, 2026, and none of the six was on the list or in Category 1. HHS's October 30 enforcement-discretion policy, logged separately, covers compounding of the six under its conditions; it does not add them to the list. - · Regulatory alert · US FDA: FDA gave notice in the Federal Register (91 FR 20465) of a July 23-24, 2026 committee meeting on seven peptides nominated for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.
The first public review of these peptides for compounding, with a public docket (FDA-2025-N-6895) that took comments until July 22.
Semaglutide
RSS feed for Semaglutide · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · News · A Gene Variant Linked to a Weaker Response to GLP-1 Drugs: What the PAM Study Found
- · News · How Many Americans Take a GLP-1? What Gallup's Surveys Actually Say
- · News · Berobenatide: Pfizer's Monthly GLP-1 Peptide Is Now in Eleven Phase 3 Trials
- · News · Retatrutide Against Semaglutide in Type 2 Diabetes: What TRANSCEND-T2D-2 Shows
- · News · Saxenda Is Being Discontinued, and Rybelsus Tablets Are Being Replaced
- · News · CagriSema's Diabetes Trials Read Out: What REIMAGINE 1, 2 and 3 Found
- · Regulatory alert · US FDA: FDA warned a Houston compounding pharmacy that its tirzepatide with niacinamide and semaglutide with vitamin B12 appear to be essentially copies of approved GLP-1 drugs, made in volumes suggesting the added vitamin is pretextual. Posted September 22.
Adding a vitamin does not by itself make a compounded GLP-1 lawful. The statute's condition is a prescriber's documented, patient-specific significant difference; pre-written prescriber determinations were part of FDA's case. - · Regulatory alert · Netherlands (IGJ): The Dutch health inspectorate imposed a penalty order on the online seller it had ordered on August 24 to stop selling retatrutide, tirzepatide and semaglutide, after the seller kept selling.
Dutch enforcement moved from an order to escalating penalties within a week. Retatrutide is approved nowhere, and the two approved GLP-1s are prescription medicines that a webshop may not supply. - · Regulatory alert · Netherlands (IGJ): The Dutch health inspectorate ordered an online webshop trading under several names to end the supply, delivery and trade of medicines containing retatrutide, tirzepatide and semaglutide.
In the EU, selling these as 'peptides' online does not take them outside medicines law; the inspectorate treats them as medicines supplied without the required licences. - · Regulatory alert · US FDA: FDA sent warning letters to five online peptide sellers in North Carolina, Florida, Texas and Arizona, calling retatrutide, semaglutide, tirzepatide and other peptides unapproved new drugs. Posted September 1.
A 'research use only' label did not decide the case: FDA read intended use from the whole website. Selling bacteriostatic water and offering a peptide calculator counted as evidence of human use. - · Regulatory alert · US FDA: FDA extended the comment period on its proposal not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list by 30 days, to July 30, 2026 (91 FR 38719).
Comments are closed. As of November 2, 2026 the Federal Register held no final determination: the June 26 extension is the newest document in docket FDA-2018-N-3240. - · News · Ozempic Pill Reaches US Pharmacies: Oral Semaglutide for Type 2 Diabetes Under the Ozempic Name
- · News · FDA Proposes Not to Add Semaglutide, Tirzepatide or Liraglutide to the 503B Bulks List — Here's What It Actually Means
- · Regulatory alert · US FDA: FDA warned a Chinese maker of peptide ingredients, including semaglutide and tirzepatide, over manufacturing-quality failures and relabelling semaglutide bought from other suppliers as its own. It had been put on Import Alert 66-40 and removed from the Import Alert 66-80 Green List on February 27. Posted May 19.
The quality problem FDA describes sits upstream of any vial: the ingredient, and who really made it. Compounders depend on that ingredient, and 503A pharmacies are exempt from the manufacturing rules that would catch it. - · Regulatory alert · US FDA: FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431, docket FDA-2018-N-3240).
A proposal, not a rule. It concerns outsourcing facilities compounding from bulk when there is no shortage; the three were never on the list, so nothing was removed. - · News · PIONEER TEENS: Oral Semaglutide Posts Positive Phase 3 Results in Pediatric Type 2 Diabetes
- · News · Wegovy HD Cleared in 54 Days: What the FDA's New Voucher Pathway Means for Peptide Drugs
- · Regulatory alert · US FDA: FDA warned an outsourcing facility making tirzepatide and semaglutide after inspectors recovered mould during a tirzepatide run and found products released despite microbial recoveries.
Even regulated compounders fail sterility; the firm had recalled multidose vials. A grey-market vial has no inspection at all before it ships. - · Regulatory alert · US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.
The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence. - · Regulatory alert · US FDA: FDA launched a 'Green List' import alert (66-80): GLP-1 ingredients such as semaglutide and tirzepatide from foreign sites it has not found compliant can be detained without physical examination.
It is aimed at ingredients for compounding, not at personal parcels: ingredients from sites on the Green List can still be imported. - · Regulatory alert · US FDA: FDA's enforcement discretion for outsourcing facilities compounding semaglutide ended.
This is when mass-market compounded semaglutide ended in the US, not in 2026. - · Regulatory alert · US FDA: FDA's enforcement discretion for 503A pharmacies compounding semaglutide copies ended when a court denied a preliminary injunction.
State-licensed pharmacies may no longer routinely compound copies of semaglutide; a compounded product needs a patient-specific clinical difference documented by the prescriber. - · Regulatory alert · US FDA: FDA declared the semaglutide shortage resolved.
The shortage listing was the legal hook for compounding copies; its end started the clock on the enforcement dates that followed.
Retatrutide
RSS feed for Retatrutide · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · New guide · Retatrutide approval tracker and TRIUMPH results
Every milestone dated and sourced, the phase 3 results both ways of counting, and approved alternatives at current prices. - · News · Lilly Is Suing Retatrutide Sellers: What the Company Alleges, and What Is Not Yet Known
- · News · Retatrutide Against Semaglutide in Type 2 Diabetes: What TRANSCEND-T2D-2 Shows
- · Correction · Corrected: Retatrutide
The TRIUMPH-4 card is gone (the trial has no peer-reviewed report); the page says TRIUMPH-3 and TRIUMPH-4 have reported only topline results, attributed to Lilly's releases, and TRANSCEND-T2D-1 is carded on its Lancet report. - · News · SYNCHRONIZE-2: Survodutide Reaches 13.1% Weight Loss in Type 2 Diabetes, and 18% Stopped for Side Effects
- · News · The Gray Market Passed $100 Million On-Chain. Spending on Testing Fell to $8 a Buyer
- · News · Retatrutide: Lilly Plans to File in Early 2027, and Offers Single-Patient Access Before Then
- · Regulatory alert · Netherlands (IGJ): The Dutch health inspectorate imposed a penalty order on the online seller it had ordered on August 24 to stop selling retatrutide, tirzepatide and semaglutide, after the seller kept selling.
Dutch enforcement moved from an order to escalating penalties within a week. Retatrutide is approved nowhere, and the two approved GLP-1s are prescription medicines that a webshop may not supply. - · Regulatory alert · Netherlands (IGJ): The Dutch health inspectorate ordered an online webshop trading under several names to end the supply, delivery and trade of medicines containing retatrutide, tirzepatide and semaglutide.
In the EU, selling these as 'peptides' online does not take them outside medicines law; the inspectorate treats them as medicines supplied without the required licences. - · Regulatory alert · US FDA: FDA sent warning letters to five online peptide sellers in North Carolina, Florida, Texas and Arizona, calling retatrutide, semaglutide, tirzepatide and other peptides unapproved new drugs. Posted September 1.
A 'research use only' label did not decide the case: FDA read intended use from the whole website. Selling bacteriostatic water and offering a peptide calculator counted as evidence of human use. - · Regulatory alert · France (ANSM): France's medicines agency told the public not to buy or inject peptides sold online, on social media or through informal contacts, naming retatrutide, BPC-157, TB-500 and GHK-Cu among others. Updated August 31.
In France these products are neither evaluated nor authorised, and their contents are uncertain. Anyone who has used them and has side effects should see a health professional. - · Regulatory alert · Australia (Victoria): Victoria's Department of Health issued a health alert after six cases of acute liver toxicity linked to unapproved products labelled Retatrutide, Reta, R-10 or R-20.
The cause may be a contaminant, so every such product is treated as at risk. Fatigue, abdominal pain, yellow skin or eyes, dark urine or easy bruising after use call for prompt medical care. - · News · TRIUMPH-1: Retatrutide Reports Up to 28.3% Weight Loss in Phase 3
- · News · A Single Peptide That Hits Five Receptors: The Quintuple Agonist
- · Regulatory alert · US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.
The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence.
PT-141
RSS feed for PT-141 · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin.
MOTS-c
RSS feed for MOTS-c · Encyclopedia entry
- · New guide · MOTS-c: the legal prescription route
Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found. - · News · Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30
- · Regulatory alert · US HHS (Office of the Secretary): HHS published a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon under set forms, routes and conditions, while FDA writes the 503A bulks list by rulemaking (91 FR 68526).
Enforcement discretion, not a rule or an approval: the policy is non-binding, HHS may revisit it, and the conditions cover sourcing, a certificate of analysis, one peptide per product, labelling, an FDA-cleared syringe and adverse-event reporting. None of the six is on the 503A list or in Category 1; emideltide is not covered, and products sold outside a pharmacy are not covered. - · Regulatory alert · US FDA advisory committee: The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for FDA's 503A bulks list and voted against emideltide, as reported (BPC-157 8–6, 1 abstention; KPV 8–6, 1 abstention; TB-500 8–6, 1 abstention; MOTS-c 7–5, 2 abstentions; emideltide 6–7, 1 abstention; semax 8–5, 1 abstention; epitalon 7–4 or 7–5, 1 abstention).
A committee recommendation is not a rule. As of November 4, 2026, FDA had posted no minutes or tallies, its 503A category list was still dated May 14, 2026, and none of the six was on the list or in Category 1. HHS's October 30 enforcement-discretion policy, logged separately, covers compounding of the six under its conditions; it does not add them to the list. - · Regulatory alert · US FDA: FDA's list of substances that may present significant safety risks now shows twelve peptides, including BPC-157, TB-500, KPV and MOTS-c, among nominations withdrawn, so they are no longer in Category 2.
Off Category 2 is not cleared: none moved to Category 1 or onto the 503A list, so 503A pharmacies still cannot compound them. Seven went to the July committee; five wait for a meeting before the end of February 2027. - · Regulatory alert · US FDA: FDA gave notice in the Federal Register (91 FR 20465) of a July 23-24, 2026 committee meeting on seven peptides nominated for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.
The first public review of these peptides for compounding, with a public docket (FDA-2025-N-6895) that took comments until July 22.
KPV
RSS feed for KPV · Encyclopedia entry
- · New guide · KPV: the legal prescription route
Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found. - · News · Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30
Ipamorelin
RSS feed for Ipamorelin · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · Regulatory alert · Brazil (ANVISA): Brazil's health regulator said GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category and are illegal for any health or aesthetic use.
In Brazil an injectable peptide cannot be sold as a supplement or a cosmetic: supplements cannot be injectable and injectable cosmetics do not exist in its rules.
GHK-Cu
RSS feed for GHK-Cu · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · Regulatory alert · Brazil (ANVISA): Brazil's health regulator said GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category and are illegal for any health or aesthetic use.
In Brazil an injectable peptide cannot be sold as a supplement or a cosmetic: supplements cannot be injectable and injectable cosmetics do not exist in its rules. - · Regulatory alert · France (ANSM): France's medicines agency told the public not to buy or inject peptides sold online, on social media or through informal contacts, naming retatrutide, BPC-157, TB-500 and GHK-Cu among others. Updated August 31.
In France these products are neither evaluated nor authorised, and their contents are uncertain. Anyone who has used them and has side effects should see a health professional. - · Regulatory alert · US FDA: FDA put GHK-Cu, except for injectable routes, back in 503A Category 1, after a nominator clarified on May 5 that it had withdrawn only the injectable nomination.
503A pharmacies may compound GHK-Cu for non-injectable use under Category 1 while FDA decides; injectable GHK-Cu is in no category and cannot be compounded. FDA plans to take GHK-Cu to the committee before the end of February 2027. - · Regulatory alert · US FDA: FDA said it will hold a second committee meeting before the end of February 2027 on five more substances: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF. No date had been set as of November 2, 2026.
Until that meeting and an FDA decision after it, none of the five can be compounded by a 503A pharmacy, except GHK-Cu for non-injectable use.
Epithalon
RSS feed for Epithalon · Encyclopedia entry
- · New guide · Epitalon: the legal prescription route
Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found. - · News · Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30
- · Regulatory alert · US HHS (Office of the Secretary): HHS published a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon under set forms, routes and conditions, while FDA writes the 503A bulks list by rulemaking (91 FR 68526).
Enforcement discretion, not a rule or an approval: the policy is non-binding, HHS may revisit it, and the conditions cover sourcing, a certificate of analysis, one peptide per product, labelling, an FDA-cleared syringe and adverse-event reporting. None of the six is on the 503A list or in Category 1; emideltide is not covered, and products sold outside a pharmacy are not covered. - · Regulatory alert · US FDA advisory committee: The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for FDA's 503A bulks list and voted against emideltide, as reported (BPC-157 8–6, 1 abstention; KPV 8–6, 1 abstention; TB-500 8–6, 1 abstention; MOTS-c 7–5, 2 abstentions; emideltide 6–7, 1 abstention; semax 8–5, 1 abstention; epitalon 7–4 or 7–5, 1 abstention).
A committee recommendation is not a rule. As of November 4, 2026, FDA had posted no minutes or tallies, its 503A category list was still dated May 14, 2026, and none of the six was on the list or in Category 1. HHS's October 30 enforcement-discretion policy, logged separately, covers compounding of the six under its conditions; it does not add them to the list. - · Regulatory alert · US FDA: FDA gave notice in the Federal Register (91 FR 20465) of a July 23-24, 2026 committee meeting on seven peptides nominated for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.
The first public review of these peptides for compounding, with a public docket (FDA-2025-N-6895) that took comments until July 22.
CJC-1295
RSS feed for CJC-1295 · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · Regulatory alert · Brazil (ANVISA): Brazil's health regulator said GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category and are illegal for any health or aesthetic use.
In Brazil an injectable peptide cannot be sold as a supplement or a cosmetic: supplements cannot be injectable and injectable cosmetics do not exist in its rules.
Cagrilintide
RSS feed for Cagrilintide · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · News · Petrelintide's Phase 2 Paper Is Out: Weight Loss Levelled Off Above 5 mg. What Else EASD 2026 Showed
- · News · CagriSema's Diabetes Trials Read Out: What REIMAGINE 1, 2 and 3 Found
- · News · REDEFINE-1 Body Composition Data: How CagriSema Affects Muscle Mass
- · Regulatory alert · US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.
The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence.
BPC-157
RSS feed for BPC-157 · Encyclopedia entry
- · New guide · What lab testing shows
The largest analysis of grey-market test results (a preprint): purity, amount, identity and endotoxin. - · New guide · BPC-157: the legal prescription route
Which forms HHS's interim 503A policy covers, the conditions, licensed pharmacies that announced it, and what FDA found. - · News · Did FDA Give Pharmacies the Green Light on Six Peptides? What Changed on October 30
- · Regulatory alert · US HHS (Office of the Secretary): HHS published a policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and physicians that compound BPC-157, TB-500, MOTS-c, KPV, semax or epitalon under set forms, routes and conditions, while FDA writes the 503A bulks list by rulemaking (91 FR 68526).
Enforcement discretion, not a rule or an approval: the policy is non-binding, HHS may revisit it, and the conditions cover sourcing, a certificate of analysis, one peptide per product, labelling, an FDA-cleared syringe and adverse-event reporting. None of the six is on the 503A list or in Category 1; emideltide is not covered, and products sold outside a pharmacy are not covered. - · Correction · Corrected: BPC-157
Half-life under 30 minutes in rats and dogs, the only species in which it has been measured. - · News · WADA's 2027 Prohibited List Writes 'Peptides' Into Its Catch-All Ban
- · Regulatory alert · US FDA advisory committee: The Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, semax and epitalon for FDA's 503A bulks list and voted against emideltide, as reported (BPC-157 8–6, 1 abstention; KPV 8–6, 1 abstention; TB-500 8–6, 1 abstention; MOTS-c 7–5, 2 abstentions; emideltide 6–7, 1 abstention; semax 8–5, 1 abstention; epitalon 7–4 or 7–5, 1 abstention).
A committee recommendation is not a rule. As of November 4, 2026, FDA had posted no minutes or tallies, its 503A category list was still dated May 14, 2026, and none of the six was on the list or in Category 1. HHS's October 30 enforcement-discretion policy, logged separately, covers compounding of the six under its conditions; it does not add them to the list. - · Regulatory alert · Brazil (ANVISA): Brazil's health regulator said GHK-Cu, BPC-157, TB-500, CJC-1295 and ipamorelin are not registered in any category and are illegal for any health or aesthetic use.
In Brazil an injectable peptide cannot be sold as a supplement or a cosmetic: supplements cannot be injectable and injectable cosmetics do not exist in its rules. - · Regulatory alert · France (ANSM): France's medicines agency told the public not to buy or inject peptides sold online, on social media or through informal contacts, naming retatrutide, BPC-157, TB-500 and GHK-Cu among others. Updated August 31.
In France these products are neither evaluated nor authorised, and their contents are uncertain. Anyone who has used them and has side effects should see a health professional. - · Regulatory alert · Louisiana: Louisiana enacted Act 374 (Senate Bill 253), effective August 1, 2026: licensing boards may not bar prescribers or pharmacists from peptides compounded by pharmacies or outsourcing facilities that comply with the federal compounding statutes.
It sounds permissive but adds no ingredient: federal law still decides what may be compounded, so BPC-157 and most popular peptides remain out of reach. It protects only compounding that is already federally lawful. - · Regulatory alert · US FDA: FDA's list of substances that may present significant safety risks now shows twelve peptides, including BPC-157, TB-500, KPV and MOTS-c, among nominations withdrawn, so they are no longer in Category 2.
Off Category 2 is not cleared: none moved to Category 1 or onto the 503A list, so 503A pharmacies still cannot compound them. Seven went to the July committee; five wait for a meeting before the end of February 2027. - · Regulatory alert · US FDA: FDA gave notice in the Federal Register (91 FR 20465) of a July 23-24, 2026 committee meeting on seven peptides nominated for the 503A bulks list: BPC-157, KPV, TB-500, MOTS-c, emideltide, semax and epitalon.
The first public review of these peptides for compounding, with a public docket (FDA-2025-N-6895) that took comments until July 22. - · Regulatory alert · Ohio: Ohio's Board of Pharmacy updated its guidance on clinic and medical-spa violations: BPC-157 and other substances in FDA's Categories 2 and 3 cannot be compounded, and it has summarily suspended more than 30 clinics and medical spas since the start of 2025.
Ohio acts on a clinic's licence rather than waiting for FDA. BPC-157 has since left Category 2, but it is still not compoundable under federal law.
Teriparatide
Parathyroid hormone (1-84)
RSS feed for Parathyroid hormone (1-84) · Encyclopedia entry
Palopegteriparatide
Liraglutide
RSS feed for Liraglutide · Encyclopedia entry
- · News · A Gene Variant Linked to a Weaker Response to GLP-1 Drugs: What the PAM Study Found
- · News · Saxenda Is Being Discontinued, and Rybelsus Tablets Are Being Replaced
- · Regulatory alert · US FDA: FDA extended the comment period on its proposal not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list by 30 days, to July 30, 2026 (91 FR 38719).
Comments are closed. As of November 2, 2026 the Federal Register held no final determination: the June 26 extension is the newest document in docket FDA-2018-N-3240. - · Regulatory alert · US FDA: FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list (91 FR 23431, docket FDA-2018-N-3240).
A proposal, not a rule. It concerns outsourcing facilities compounding from bulk when there is no shortage; the three were never on the list, so nothing was removed.
FOXO4-DRI
Exenatide
DSIP
Vosoritide
VK2735
RSS feed for VK2735 · Encyclopedia entry
- · News · VK2735: Viking Starts Its Oral Phase 3 Trials and Reports Less-Frequent Maintenance Dosing
- · Correction · Corrected: VK2735
In VENTURE, mean weight fell 9.1% to 14.7% on the drug and 1.7% on placebo over 13 weeks; phase 3 trials of the injection began in June 2025.
Rusfertide
Visoluten
RSS feed for Visoluten · Encyclopedia entry
- · Correction · Corrected: Visoluten
The unfindable citation is gone; no paper indexed on PubMed names Visoluten, and the indexed retinal preparation, Retinalamin, is a different product.
Vesugen
RSS feed for Vesugen · Encyclopedia entry
- · Correction · Corrected: Vesugen
Small uncontrolled studies in people exist (under the spelling Vezugen, from 2014), including 41 men with vascular erectile dysfunction; none had a placebo group.
Ventfort
RSS feed for Ventfort · Encyclopedia entry
- · Correction · Corrected: Ventfort
The unfindable citation is gone; no paper indexed on PubMed names Ventfort and no sequence for it is published.
Trevogrumab
RSS feed for Trevogrumab · Encyclopedia entry
- · Correction · Corrected: Trevogrumab
Trevogrumab is in COURAGE, a phase 2 obesity trial adding it, alone or with garetosmab, to semaglutide (NCT06299098).
Testagen
RSS feed for Testagen · Encyclopedia entry
- · Correction · Corrected: Testagen
The unfindable citation is gone; what was studied (labelled testagen entering the nucleus of HeLa cells) is cited, and no study shows an effect on the testis.
Syn-Ake
RSS feed for Syn-Ake · Encyclopedia entry
- · Correction · Corrected: Syn-Ake
Syn-Ake is β-Ala-Pro-Dab benzylamide as its diacetate salt, formula C23H37N5O7; the unfindable citation is gone.
Prostamax
RSS feed for Prostamax · Encyclopedia entry
- · Correction · Corrected: Prostamax
The unfindable citation and the Prostagen alias are gone. The six indexed papers that name it study chromatin in white blood cells from people aged 75 to 88 and rat tissue explants; none gave it to people. - · Regulatory alert · US FDA: FDA warned a Florida online peptide seller that two products it sold, gonadorelin and one sold as Prostamax, are unapproved new drugs. Posted July 16.
Another letter that looks past 'research use only' and 'not for human consumption' labelling to what the website shows.
PEG-MGF
RSS feed for PEG-MGF · Encyclopedia entry
- · Correction · Corrected: PEG-MGF
MGF is the 24 C-terminal residues of the IGF-1Eb splice variant; no pharmacokinetic study of PEG-MGF exists, so no half-life is given. - · Regulatory alert · US FDA: FDA said it will hold a second committee meeting before the end of February 2027 on five more substances: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF. No date had been set as of November 2, 2026.
Until that meeting and an FDA decision after it, none of the five can be compounded by a 503A pharmacy, except GHK-Cu for non-injectable use.
PB-718
RSS feed for PB-718 · Encyclopedia entry
- · Correction · Corrected: PB-718
PB-718 is a long-acting dual agonist of the GLP-1 and glucagon receptors, developed for obesity and MASH; a US phase 1 and a Chinese phase 1b/2a are complete and unpublished.
Palmitoyl Tripeptide-38
RSS feed for Palmitoyl Tripeptide-38 · Encyclopedia entry
- · Correction · Corrected: Palmitoyl tripeptide-38
Formula C33H65N5O7S, molecular weight 676.0.
Palmitoyl Tetrapeptide-7
RSS feed for Palmitoyl Tetrapeptide-7 · Encyclopedia entry
- · Correction · Corrected: Palmitoyl tetrapeptide-7
Aliases are Pal-GQPR, palmitoyl-GQPR, palmitoyl tetrapeptide-3 and Pal-Gly-Gln-Pro-Arg (PubChem lists tetrapeptide-3 as the same compound); the IL-6 claim is described as unsourced, and what it did alone (more type III collagen in UV-exposed fibroblasts) is cited.
NPAS3 Research Peptide
RSS feed for NPAS3 Research Peptide · Encyclopedia entry
- · Correction · Corrected: NPAS3 peptide
No published study describes an NPAS3 peptide or gives a sequence for it; the NPAS3 findings concern the gene and protein.
NA-Selank Amidate
RSS feed for NA-Selank Amidate · Encyclopedia entry
- · Correction · Corrected: N-acetyl Selank amidate
No study of this derivative exists; whether its end caps change how long Selank lasts is unknown, and no dose is printed.
Mod GRF 1-29
RSS feed for Mod GRF 1-29 · Encyclopedia entry
- · Correction · Corrected: Mod GRF 1-29
No study has given this unconjugated peptide to animals or people; anti-doping laboratories have identified it in seized products. No dose is printed.
KR-12
RSS feed for KR-12 · Encyclopedia entry
- · Correction · Corrected: KR-12
No study giving KR-12 or a derivative to people is on PubMed, and ClinicalTrials.gov lists no KR-12 trial; its half-life has not been measured.
KN056
RSS feed for KN056 · Encyclopedia entry
- · Correction · Corrected: KN056
KN056 is a recombinant GLP-1 variant fused to an antibody Fc fragment; its one published trial gave single doses to 30 healthy men.
HRS-9531
RSS feed for HRS-9531 · Encyclopedia entry
- · Correction · Corrected: HRS9531
In its first human study, four weekly doses lowered weight by 6.7% to 9.6% against 1.4% on placebo, with a half-life of 7 to 8 days; the phase 3 figure is labelled as a company announcement. - · News · Petrelintide's Phase 2 Paper Is Out: Weight Loss Levelled Off Above 5 mg. What Else EASD 2026 Showed
FGL Peptide
RSS feed for FGL Peptide · Encyclopedia entry
- · Correction · Corrected: FGL peptide
The unfindable citation is gone; the rat amyloid-beta findings are cited to the 2007 paper that reports them.
Endoluten
RSS feed for Endoluten · Encyclopedia entry
- · Correction · Corrected: Endoluten
A PubMed search for its name finds no record and no composition is published; epithalamin and epitalon have their own studies and entries.
Eftansomatropin alfa
RSS feed for Eftansomatropin alfa · Encyclopedia entry
- · Correction · Corrected: Eftansomatropin alfa
Not approved anywhere; a phase 3 in Chinese children met non-inferiority and a licence application is under review in China. The adult phase 2 is cited to its paper.
Cortagen
RSS feed for Cortagen · Encyclopedia entry
- · Correction · Corrected: Cortagen
Its studies are in rats, mice and chickens (for example, faster nerve regrowth after a cut sciatic nerve in rats); none has tested it in people.
Chonluten
RSS feed for Chonluten · Encyclopedia entry
- · Correction · Corrected: Chonluten
The only study on PubMed to name it tested it in a human monocyte cell line; no animal, lung-tissue or human study was found.
Cerluten
RSS feed for Cerluten · Encyclopedia entry
- · Correction · Corrected: Cerluten
No seller is named. No paper on PubMed names Cerluten and no composition is published, so what it contains cannot be checked; sellers market it for the brain.
Cecropin
RSS feed for Cecropin · Encyclopedia entry
- · Correction · Corrected: Cecropin
No half-life is given (none is reported for any cecropin in the sources read); the mechanism is now sourced: cecropin A kills Gram-negative bacteria by dissipating membrane ion gradients.
Bronchogen
RSS feed for Bronchogen · Encyclopedia entry
- · Correction · Corrected: Bronchogen
Its evidence is cell cultures, DNA experiments and a rat model of COPD from its developers' group; no study has given it to people, and in Russia it is listed as a dietary supplement, not a medicine.
BRN2 (POU3F2) Research Peptide
RSS feed for BRN2 (POU3F2) Research Peptide · Encyclopedia entry
- · Correction · Corrected: BRN2
BRN2 is a transcription factor, not one peptide; the published fragments were tested against melanoma in cells and mice, none for the brain and none in people.
Biotinoyl Tripeptide-1
RSS feed for Biotinoyl Tripeptide-1 · Encyclopedia entry
- · Correction · Corrected: Biotinoyl tripeptide-1
Formula C24H38N8O6S, molecular weight 566.7 (biotin bonded to Gly-His-Lys).
AZD6234
RSS feed for AZD6234 · Encyclopedia entry
- · Correction · Corrected: AZD6234
ClinicalTrials.gov lists 14 trials, including a completed 26-week phase 2b and three phase 3 trials recruiting since August 2026.
AHK-Cu
RSS feed for AHK-Cu · Encyclopedia entry
- · Correction · Corrected: AHK-Cu
The only study that names it is a 2007 culture of human scalp follicles; no animal or human study has tested it.
Adipotide
RSS feed for Adipotide · Encyclopedia entry
- · Correction · Corrected: Adipotide
Its one human trial, a phase 1 in obese men with prostate cancer (NCT01262664), started in 2012, enrolled 4 patients and was terminated in January 2019 with no results posted or published.
5-Amino-1MQ
RSS feed for 5-Amino-1MQ · Encyclopedia entry
- · Correction · Corrected: 5-Amino-1MQ
No dose is printed: no published study has given 5-Amino-1MQ to people, and it has never been tested in people.
CagriSema
RSS feed for CagriSema · Encyclopedia entry
- · Correction · Corrected: CagriSema
REDEFINE 2 gave 13.7% weight loss at 68 weeks against 3.4% on placebo (treatment-policy estimand). - · News · CagriSema Against Tirzepatide in Type 2 Diabetes: What REIMAGINE 5 Shows
- · News · CagriSema's Diabetes Trials Read Out: What REIMAGINE 1, 2 and 3 Found
- · News · ADA 2026 Preview: The Incretin Readouts to Watch in New Orleans
- · News · REDEFINE-1 Body Composition Data: How CagriSema Affects Muscle Mass
Orforglipron
RSS feed for Orforglipron · Encyclopedia entry
- · News · Elecoglipron in Phase 2: What the VISTA and SOLSTICE Trials Show
- · Regulatory alert · US FDA: FDA published a major revision of Import Alert 66-80, which lets it detain GLP-1 bulk ingredients from foreign sites not on its Green List without examination, updating the Green List criteria and adding product codes, including one for orforglipron.
The alert governs the raw ingredient that compounders import, not a finished product a patient buys. FDA says 21% of the 48 GLP-1 ingredient sites it reviewed were noncompliant, and that some sites registered, offered ingredients for import, refused records requests and deregistered. - · News · Ozempic Pill Reaches US Pharmacies: Oral Semaglutide for Type 2 Diabetes Under the Ozempic Name
- · News · Foundayo (Orforglipron) Approved: A Small-Molecule GLP-1 Pill for Weight Loss
ECC5004
Danuglipron
GLP-1
RSS feed for GLP-1 · Encyclopedia entry
- · Regulatory alert · US FDA: FDA published a major revision of Import Alert 66-80, which lets it detain GLP-1 bulk ingredients from foreign sites not on its Green List without examination, updating the Green List criteria and adding product codes, including one for orforglipron.
The alert governs the raw ingredient that compounders import, not a finished product a patient buys. FDA says 21% of the 48 GLP-1 ingredient sites it reviewed were noncompliant, and that some sites registered, offered ingredients for import, refused records requests and deregistered. - · Regulatory alert · US FDA: FDA warned a Houston compounding pharmacy that its tirzepatide with niacinamide and semaglutide with vitamin B12 appear to be essentially copies of approved GLP-1 drugs, made in volumes suggesting the added vitamin is pretextual. Posted September 22.
Adding a vitamin does not by itself make a compounded GLP-1 lawful. The statute's condition is a prescriber's documented, patient-specific significant difference; pre-written prescriber determinations were part of FDA's case. - · Regulatory alert · China (State Council): China's revised drug regulations (Order No. 828) took effect, barring online retail and online prescribing of higher-risk medicines.
The online route through which GLP-1 injections had been reaching weight-loss buyers in China was closed. - · Regulatory alert · US FDA: FDA warned a state-licensed compounding pharmacy that released products, including a compounded tirzepatide injection, among nine lots that failed sterility testing.
A compounded GLP-1 is only as safe as the pharmacy's sterile practice; checking that a pharmacy is licensed and has no recent FDA letter is part of choosing one. - · Regulatory alert · US FDA: FDA launched a 'Green List' import alert (66-80): GLP-1 ingredients such as semaglutide and tirzepatide from foreign sites it has not found compliant can be detained without physical examination.
It is aimed at ingredients for compounding, not at personal parcels: ingredients from sites on the Green List can still be imported. - · Regulatory alert · European Union (EMA and HMA): The European Medicines Agency and the Heads of Medicines Agencies warned of a sharp rise in illegal medicines advertised and sold online as GLP-1 receptor agonists.
In the EU, GLP-1 drugs are prescription medicines, to be bought only from authorised pharmacies or retailers on a prescription. - · Regulatory alert · US FDA: FDA's enforcement discretion for outsourcing facilities compounding semaglutide ended.
This is when mass-market compounded semaglutide ended in the US, not in 2026. - · Regulatory alert · US FDA: FDA's enforcement discretion for 503A pharmacies compounding semaglutide copies ended when a court denied a preliminary injunction.
State-licensed pharmacies may no longer routinely compound copies of semaglutide; a compounded product needs a patient-specific clinical difference documented by the prescriber. - · Regulatory alert · US FDA: FDA's enforcement discretion for outsourcing facilities compounding tirzepatide ended.
Outsourcing facilities lost the shortage-era route to compounding tirzepatide. - · Regulatory alert · US FDA: FDA's enforcement discretion for 503A pharmacies compounding tirzepatide copies ended when a court denied a preliminary injunction.
State-licensed pharmacies lost the routine route to compounding tirzepatide first. - · Regulatory alert · US FDA: FDA declared the semaglutide shortage resolved.
The shortage listing was the legal hook for compounding copies; its end started the clock on the enforcement dates that followed.
Somatropin (HGH)
CNP
Petrelintide
Insulin icodec
Insulin efsitora alfa
Icotrokinra
Enlicitide
Gonadorelin
RSS feed for Gonadorelin · Encyclopedia entry
- · Regulatory alert · US FDA: FDA warned a Florida online peptide seller that two products it sold, gonadorelin and one sold as Prostamax, are unapproved new drugs. Posted July 16.
Another letter that looks past 'research use only' and 'not for human consumption' labelling to what the website shows.
Glucagon
Melanotan II
RSS feed for Melanotan II · Encyclopedia entry
- · Regulatory alert · US FDA: FDA said it will hold a second committee meeting before the end of February 2027 on five more substances: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF. No date had been set as of November 2, 2026.
Until that meeting and an FDA decision after it, none of the five can be compounded by a 503A pharmacy, except GHK-Cu for non-injectable use.
LL-37
RSS feed for LL-37 · Encyclopedia entry
- · Regulatory alert · US FDA: FDA said it will hold a second committee meeting before the end of February 2027 on five more substances: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF. No date had been set as of November 2, 2026.
Until that meeting and an FDA decision after it, none of the five can be compounded by a 503A pharmacy, except GHK-Cu for non-injectable use.
Dihexa
RSS feed for Dihexa · Encyclopedia entry
- · Regulatory alert · US FDA: FDA said it will hold a second committee meeting before the end of February 2027 on five more substances: LL-37, GHK-Cu, dihexa, melanotan II and PEG-MGF. No date had been set as of November 2, 2026.
Until that meeting and an FDA decision after it, none of the five can be compounded by a 503A pharmacy, except GHK-Cu for non-injectable use.
Mazdutide
RSS feed for Mazdutide · Encyclopedia entry
- · Regulatory alert · US FDA: FDA warned two online sellers, in California and Arizona, that retatrutide, tirzepatide, semaglutide, cagrilintide and mazdutide, sold under code names such as 'GLP-1-R peptide' and 'GLP1-T', are unapproved new drugs. Posted April 7.
The code names did not hide the drugs, and 'laboratory research purposes only' labels did not change FDA's finding. Bacteriostatic water sold alongside was again part of the evidence.